Partnering to advance groundbreaking programs in precision oncology
We are committed to partnering with the best and brightness minds in academia, biotechnology and pharma to advance programs in targeted/precision oncology. We partner with teams that share our vision to advance promising programs in potentially lethal diseases where the unmet need remains frustratingly high.
We are actively seeking opportunities to collaborate in any of the following areas:
Precision oncology programs across solid tumors
Neuro-oncology programs that select for genetically defined tumors
Novel mechanisms of action; either first-in-class or potentially best-in-class
Both pre-clinical and clinical stage assets
The management team at Chimerix has substantial experience in oncology drug development, manufacturing scale up and global regulatory expertise to accelerate precision oncology programs to approval. For more information about how we might work together, please contact Mike Andriole, Chief Business Officer, at [email protected].
Key benefits of collaborating with Chimerix include:
Strong culture of execution
Extensive clinical development and regulatory experience
Creativity in constructing partnerships
Commitment to professional alliance management
Track record of pioneering novel therapeutic targets for molecularly-defined diseases
Mike Andriole, Chief Business Officer
“Chimerix has a long history of partnerships to develop novel and/or first-in-class treatments for patients globally. Through our collaborations, we aim to leverage the unique strengths of both organizations to accelerate programs to approval and commercialization. Our experience with diverse partnerships across large pharmaceutical companies, smaller biotechs, geographic partnerships, government agencies and academic research institutions all have a common thread: we invest wisely, operate with high integrity, impart a sense of urgency and we are honest about where the data lead us.”
